Sattva Group Partners with Sankalp India Foundation to Launch Blood Donation Drive on World Thalassemia Day
Initiated on World Thalassemia Day, this significant campaign will unfold over the next three months across Sattva's IT campuses in Bengaluru, beginning with Sattva Knowledge Court and Sattva Mind Comp Tech Park. Thalassemia affects the body's ability to produce hemoglobin and red blood cells, making frequent transfusions a non-negotiable part of treatment. Thus, this drive is more than just a collection of blood donations—it's a call to the corporate community to unite and address the urgent need for a stable supply of safe blood.
Despite being one of the most common genetic disorders in India, with over 10,000 children born with thalassemia major each year, awareness remains limited. This drive is more than just a collection of blood donations; it's a call to the corporate community to unite in ensuring a stable supply of safe blood for those in need.
'Our partnership with Sankalp India Foundation acknowledges the profound reality that surrounds us—right now, real people in our communities are facing challenges that we can help solve," stated Shivam Agarwal, VP of Strategy Growth at Sattva Group. "We invite all corporate entities within our campuses to join us because countless individuals await critical support—from life-saving blood donations to the fundamental resources necessary for their wellbeing. These are the ongoing realities of people in our community. Corporate India must recognize that our collective strength, when channeled with purpose, can transform lives and create lasting impact. Together, we can bridge gaps and create meaningful change that makes tomorrow better than today for those who need it most'
Each blood donation camp will offer pre-donation health checks, enlightening sessions about thalassemia, and expert medical support to ensure a safe and seamless process for donors. Participants will receive educational materials illustrating how one unit of blood can profoundly change lives.
'We are immensely grateful to Sattva Group for their proactive approach in supporting our cause,' said *Rajat Kumar Agarwal, President Sankalp India Foundation. "We are honoured to partner with the Sattva Group for the voluntary blood donation campaign. This collaboration marks a powerful step towards solving one of the most urgent needs of thalassemia care: access to safe, regular blood transfusions. With the support of Sattva Group, we are working to ensure a steady, dependable blood supply for more than 2,500 thalassemia patients across our nationwide network of day care centres. For these children, every transfusion is not just a treatment, it's a lifeline. Every unit of blood donated is a gift of strength, of hope, of life itself. We invite everyone to be part of this movement and stand with these young fighters who battle thalassemia every single day."
By donating blood, professionals become part of a movement that extends compassion beyond the workplace and directly supports those battling thalassemia. Together, Sattva Group and Sankalp India Foundation invite the corporate community to participate in this essential initiative.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 days ago
- The Hindu
Bengaluru-based NGO's hemoglobinopathy prevention programme has averted 201 affected births across five States
In the absence of regular screening for pregnant women to check inherited blood disorders in the country, a Bengaluru-based NGO's hemoglobinopathy prevention programme has helped avert 201 affected births across five States. Inherited blood disorders such as thalassemia and sickle cell disease (also known as hemoglobinopathies) inflict lifelong suffering, including repeated transfusions, painful complications, disability, and early death. 1.9 lakh screened In the last four years, the NGO, Sankalp India Foundation, screened over 1.9 lakh women in 81 districts across Maharashtra, Madhya Pradesh, Gujarat, Karnataka, and Andhra Pradesh. It was possible to prevent 201 births with severe hemoglobinopathies. These included 91 sickle cell disease, 76 thalassemia major, 27 sickle-beta thalassemia, and seven other hemoglobinopathies. Proactive measures, including genetic counseling and prenatal screening, enabled families to make informed decisions about continuing or terminating pregnancies based on fetal test results. 28 from Karnataka The 201 births include 28 from Karnataka, 123 from Maharashtra, 12 from Andhra Pradesh, 13 from Gujarat, and 25 from Madhya Pradesh. 'The number of affected births that have been prevented corresponds to the carrier (of mutated genes that cause the hemoglobinopathies but do not have the disease themselves) rates in these States,' Rajat Kumar Agarwal, president of Sankalp India Foundation, told The Hindu on Saturday. Pointing out that the programme is a scalable model of national importance, Mr. Agarwal said, 'As India commits to eliminating sickle cell disease by 2047, this programme offers a working blueprint of how to make that vision a reality.' This impact was only possible because of strong partnerships with National Health Missions in the five States, district health authorities, local health workers, donor institutions, and other stakeholders. It reflects a model of public-private collaboration rooted in equity, trust, and local leadership, he said. As many as 87 centre coordinators and six regional coordinators trained and embedded in the Obstetrics/ Gynaecology departments in district hospitals were at the frontline. 'They counselled parents-to-be, mobilised timely testing, supported prenatal diagnosis, and offered continuity of care with unwavering compassion and clarity,' he added. Hardest decision Couples, who were counselled and tested, said they had no idea they were both carriers. 'Following the genetic testing, terminating the pregnancy was the hardest decision of our lives. But, we were not prepared to see our child suffer lifelong,' said Jayshree and M. Ravi, who were counselled and tested through the NGO at Tumkuru district hospital. 'The programme gave us knowledge and choices to ensure a healthy future for our child,' said Seema and Mahesh from Alirajpur in Madhya Pradesh. Sundar Periyavan, lab director of Sankalp Labs and former Head of Haematology and Transfusion Medicine at NIMHANS, said accurate and timely diagnostics are the lifeline of this programme. Quick and precise 'Every hour counts, and our labs ensure fast, accurate, and actionable results through high-performance liquid chromatography (HPLC). The families receive clear answers when it matters most,' the doctor said. The clinical framework and quality systems of this programme were conceptualised by Lawrence Faulkner, medical director of Sankalp and founder of Cure2Children, Italy, an international haematologist. 'Sankalp's antenatal screening model, grounded in precision diagnostics and community engagement, has transformed the way we approach hemoglobinopathy prevention,' said Dr. Faulkner. (Names of the couples have been changed).
The Hindu
10-05-2025
- The Hindu
Coal India Limited felicitates CMC for Thalassemia care
Coal India Limited has awarded the Department of Haematology of the Christian Medical College (CMC) in Vellore for its work in thalassemia treatment and care A release said that the award – as part of the CIL's Thalassemia Bal Sewa Yojana (TBSY) programme – was presented by Union Minister of Coal and Mines G. Kishan Reddy to Gomathi Joseph, Senior Social Worker of the department, and her team at a function in New Delhi recently. The award is titled 'Gift of Life through Thalassemia Bal Sewa Yojana', a Corporate Social Responsibility (CSR) initiative of the CIL, and the scheme aims at supporting underprivileged children suffering from thalassemia. As many as 208 children have undergone life-saving transplants at the CMC under the scheme, to mark the World Thalassemia Day. Vikram Mathews, Director, CMC, appreciated the efforts of the Haematology Department for securing the award, the release added.
News18
09-05-2025
- News18
Planning A Family? Here's Why Thalassemia Screening Before Marriage Matters
Last Updated: Thalassemia, hereditary blood disorder, impairs the body's ability to produce sufficient haemoglobin. With early screening, this disorder can be entirely avoided. Observed annually on May 8, World Thalassemia Day serves as a vital reminder to acknowledge the challenges faced by those living with thalassemia, while also promoting efforts to prevent the condition altogether. More than just a medical concern, thalassemia is a social issue that demands greater awareness, public acceptance, and a proactive stance on prevention, particularly through premarital screening. With early intervention and informed choices, this lifelong and often debilitating disorder can be entirely avoided. Thalassemia is a hereditary blood disorder that impairs the body's ability to produce sufficient haemoglobin, an essential component of red blood cells responsible for transporting oxygen. As a result, individuals with thalassemia suffer from chronic anaemia and often rely on regular blood transfusions to survive. However, these transfusions offer only temporary relief and come with long-term risks, including iron overload, organ damage, and increased vulnerability to infections. They also impose significant emotional and financial strain on patients and their families. What many don't realise is that thalassemia is entirely preventable. The condition arises only when both parents are silent carriers of the faulty gene—individuals who typically show no symptoms and may remain unaware of their status without a specific blood test. Tragically, many couples discover they are carriers only after the birth of a child with thalassemia major, a diagnosis that brings lifelong challenges. Dr. Shubham Bhattacharya, Hematologist at CMRI Hospital Kolkata, says, 'From an affected perspective, if both parents are carriers, there would be a 25% risk during each pregnancy that a 50% chance of producing a child who is also a carrier, and only a 25% chance of a completely unaffected child. But this genetic lottery can be avoided through a simple blood test, such as Haemoglobin Electrophoresis or HPLC (High-Performance Liquid Chromatography)—conducted before marriage or family planning." 'If a couple is found to be at risk, genetic counselling becomes critical. Should they decide to proceed with having children, prenatal diagnostic testing during the first trimester of pregnancy (preferably before 12 weeks) can help detect whether the fetus is affected by thalassemia major. Based on the results, couples can explore their options and receive appropriate support. That said, prevention before conception remains the best path forward—medically, emotionally, and ethically," added Dr Bhattacharya. Thalassemia may be genetic, but with the right awareness and timely action, it can be prevented. First Published:
